Peramivir Patent Expiration
Peramivir is Used for treating acute uncomplicated influenza in patients 6 months and older. It was first introduced by Biocryst Pharmaceuticals Inc
Peramivir Patents
Given below is the list of patents protecting Peramivir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rapivab | US8778997 | Antiviral treatments | May 07, 2027 | Biocryst |
| Rapivab | US10391075 | Antiviral treatments | Feb 12, 2027 | Biocryst |
| Rapivab | US6562861 | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec 16, 2023
(Expired) | Biocryst |
| Rapivab | US6503745 | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov 05, 2019
(Expired) | Biocryst |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Peramivir's patents.
Latest Legal Activities on Peramivir's Patents
Given below is the list recent legal activities going on the following patents of Peramivir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jan, 2026 | US8778997 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10391075 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Dec, 2021 | US8778997 |
| Patent Issue Date Used in PTA Calculation Critical
| 27 Aug, 2019 | US10391075 |
| Recordation of Patent Grant Mailed Critical
| 27 Aug, 2019 | US10391075 |
| Email Notification Critical
| 08 Aug, 2019 | US10391075 |
| Issue Notification Mailed Critical
| 07 Aug, 2019 | US10391075 |
| Dispatch to FDC | 29 Jul, 2019 | US10391075 |
| Application Is Considered Ready for Issue Critical
| 19 Jul, 2019 | US10391075 |
| Issue Fee Payment Verified Critical
| 12 Jul, 2019 | US10391075 |
Peramivir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Peramivir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy and Safety of Inhaled Peramivir Solution for the Treatment of Adults With Uncomplicated Influenza | Capital Medical University | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. | BioCryst Pharmaceuticals | NA |
WITHDRAWN
(Jun 1, 2026)
| PHASE3 |
| Intramuscular Peramivir for the Treatment of Uncomplicated Influenza | BioCryst Pharmaceuticals | NA |
WITHDRAWN
(May 1, 2026)
| PHASE3 |